Effects of Bisphosphonates on OI-Related Hearing Loss
NCT04152551
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Osteogenesis Imperfecta-related hearing loss usually occurs in individuals with mild (type I) OI and is much earlier in onset than age-related hearing loss, with the majority of individuals experiencing some minor hearing loss in their 20s. Bisphosphonates have been successfully used to treat otosclerosis, a common cause of hearing loss similar to OI-related hearing loss.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Osteogenesis Imperfecta
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 6 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Hospital for Special Surgery, New York
- Last updated on ClinicalTrials.gov
- April 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- Hospital for Special Surgery · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.